Phase 2, Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 For Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Advanced Non-Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Incidence of Adverse Events
Participant incidence of adverse events
4 months
Yes
MD
Study Director
Amgen
Austria: Secretariat of Health
20050154
NCT00413283
December 2006
February 2009
Name | Location |
---|---|
Research Site | Mesa, Arizona |
Research Site | Anaheim, California |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Arlington Heights, Illinois |
Research Site | Ames, Iowa |
Research Site | Ashland, Kentucky |
Research Site | Baton Rouge, Louisiana |
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |
Research Site | Billings, Montana |
Research Site | Belleville, New Jersey |
Research Site | Albany, New York |
Research Site | Enid, Oklahoma |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |